Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit

3 Feb 2023

Abstract excerpt

We aimed to determine microbial signature linked with lung cancer (LC) diagnosis and to define taxa linked with durable clinical benefit (DCB) of advanced LC patients. Stool samples for microbial 16S amplicon sequencing and clinical data were collected from 75 LC patients (50 of which were treated with checkpoint inhibitors) and 31 matched healthy volunteers. We compared LC to healthy controls and patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Screening and Detection
Share to Gut microbiota and health
Share to Mycobacterium research and diagnosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36737654
DOI: 10.1038/s41598-023-29136-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefitPMID 36737654Read ↗

Human Microbiome as Clinical Biomarkers for Respiratory Tract CancersSemantic proximity Read ↗

Gut Microbiota a Novel Source of Biomarkers for Immunotherapy in Non-small Cell Lung Cancer (NSCLC)Semantic proximity Read ↗

Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivorsSemantic proximity Read ↗

Microbial Determinants of Immune Activation and Clinical Outcome in Lung Tumor SubtypesSemantic proximity Read ↗

Specific gut microbiome signature predicts the early-stage lung cancerSemantic proximity Read ↗

Salivary Microbial Signature Highlighting Actinomyces as a Predictor of Immune-Checkpoint Inhibitor Response in Advanced Non–Small Cell Lung Cancer.Semantic proximity Read ↗

Gut Metatranscriptomics Based De Novo Assembly Reveals Microbial Signatures Predicting Immunotherapy outcomes in Non-Small Cell Lung CancerSemantic proximity Read ↗

Distinct gut virome profiles are associated with response to anti-PD-1 therapy in non-small cell lung cancerSemantic proximity Read ↗

Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancerSemantic proximity Read ↗

Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut MicrobiotaSemantic proximity Read ↗

Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer PatientsSemantic proximity Read ↗

Predictive power of different <i>Akkermansia</i> phylogroups in clinical response to PD-1 blockade against non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.